Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status
This study is currently recruiting participants.
Verified May 2013
by National Institute of Allergy and Infectious Diseases (NIAID)
Study NCT01040091 Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received on December 23, 2009. Last Updated on May 3, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infections
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
More general conditions related to this trial
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Emtricitabine (FTC)
Tenofovir disoproxil fumarate (TDF)
Efavirenz (EFV)
Truvada
Additional drug interventions recognized in this trial
Efavirenz
Emtricitabine
Tenofovir
Tenofovir disoproxil
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)
Back to top of Main Content
